ES2913063T3 - Ensayo y medicamento - Google Patents

Ensayo y medicamento Download PDF

Info

Publication number
ES2913063T3
ES2913063T3 ES15701244T ES15701244T ES2913063T3 ES 2913063 T3 ES2913063 T3 ES 2913063T3 ES 15701244 T ES15701244 T ES 15701244T ES 15701244 T ES15701244 T ES 15701244T ES 2913063 T3 ES2913063 T3 ES 2913063T3
Authority
ES
Spain
Prior art keywords
rna
virus
segment
influenza
segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15701244T
Other languages
English (en)
Spanish (es)
Inventor
Nigel J Dimmock
Andrew J Easton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Application granted granted Critical
Publication of ES2913063T3 publication Critical patent/ES2913063T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES15701244T 2014-01-16 2015-01-16 Ensayo y medicamento Active ES2913063T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1400752.0A GB2522615A (en) 2014-01-16 2014-01-16 Assay and medicament
PCT/GB2015/050094 WO2015107357A1 (en) 2014-01-16 2015-01-16 Assay and medicament

Publications (1)

Publication Number Publication Date
ES2913063T3 true ES2913063T3 (es) 2022-05-31

Family

ID=50239057

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15701244T Active ES2913063T3 (es) 2014-01-16 2015-01-16 Ensayo y medicamento

Country Status (8)

Country Link
US (3) US20160333321A1 (enExample)
EP (2) EP4085917A1 (enExample)
JP (1) JP6781045B2 (enExample)
DK (1) DK3094338T3 (enExample)
ES (1) ES2913063T3 (enExample)
GB (1) GB2522615A (enExample)
PL (1) PL3094338T3 (enExample)
WO (1) WO2015107357A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046689A1 (en) * 2021-02-18 2022-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408424D0 (en) * 2004-04-15 2004-05-19 Univ Warwick Viral assay
NZ555118A (en) * 2004-11-11 2009-09-25 Solvay Biologicals Bv Defective influenza virus particles incapable of producing functional polymerase
US8435508B2 (en) * 2006-05-24 2013-05-07 The University Of Warwick Cloned defective interfering influenza A virus
GB2437799B (en) * 2006-05-24 2008-08-13 Univ Warwick Defective interfering virus
GB0822672D0 (en) * 2008-12-12 2009-01-21 Univ Warwick Anti-viral protection with viruses containing a defective genome
US20130156733A1 (en) * 2011-12-20 2013-06-20 Philip I. Marcus Influenza virus populations, methods of use and methods of making thereof

Also Published As

Publication number Publication date
WO2015107357A1 (en) 2015-07-23
GB201400752D0 (en) 2014-03-05
EP3094338A1 (en) 2016-11-23
US11339374B2 (en) 2022-05-24
DK3094338T3 (da) 2022-05-23
US20200231939A1 (en) 2020-07-23
PL3094338T3 (pl) 2022-08-08
GB2522615A (en) 2015-08-05
JP6781045B2 (ja) 2020-11-04
US20220325251A1 (en) 2022-10-13
EP4085917A1 (en) 2022-11-09
JP2017504331A (ja) 2017-02-09
US20160333321A1 (en) 2016-11-17
EP3094338B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
US11384339B2 (en) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
Powell et al. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity
ES2563402T3 (es) Señal para el empaquetamiento de vectores del virus de la gripe
US10494613B2 (en) Generation of infectious influenza viruses from virus-like particles
Meng et al. Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA
JP2017529084A (ja) ピチンデウイルスのリバースジェネティクス系及び使用方法
CN107208071B (zh) 用于流感病毒的减弱活疫苗
Wu et al. A live bivalent influenza vaccine based on a H9N2 virus strain
US20230414745A1 (en) Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain
US20220325251A1 (en) Assay and medicament
CN101454023B (zh) 干扰缺损病毒
Groenke Molecular mechanism of virus attenuation by codon pair deoptimization
Naito et al. Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant
Abbas Special Issues
White et al. A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. Viruses 2021, 13, 1278
Moreira Bat influenza viruses: insights in the molecular biology and characterization of infectious viruses
Turnbull Role of the NS segment of Influenza A virus in setting host range and pathogenicity
Cox Increasing the safety of the Live Attenuated Influenza Virus Vaccine
Williams Influenza A virus Genomic Reassortment and Packaging
Pfisterer Optimization of a ray-based merit function using third-order residual aberrations
Jardetzky Oral 1 STRUCTURE AND ACTIVATION OF PARAMYXOVIRUS FUSION GLYCOPROTEINS
Cauldwell Investigating the mechanisms of influenza polymerase host adaptation
Bow Investigation of the role of the RNA-dependant RNA polymerase in the transcription and replication of the 1918 pandemic Influenza A virus
HK1244506B (zh) 用於流感病毒的减弱活疫苗